Founder and Managing Partner of a newly-formed venture capital fund focused on founding and building biotechnology companies dedicated to the discovery, development and commercialization of new medicines with potential to greatly advance or transform the care of serious diseases.

Stoke Therapeutics is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. The company develops antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. The company's proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, is believed to enable delivery disease-modifying therapies in a highly precise, durable and controlled manner. Stoke's lead program, STK-001 is expected to enter human clinical trials for Dravet syndrome, a devastating epileptic syndrome, during 2020.

Chinook Therapeutics is developing precision medicines for the treatment of severe diseases of the kidney. The company was formed to exploit the convergence of new insights into pathophysiology and target biology, new clinical development tools and outcome measures and clarified regulatory paths that enable the development of important new therapies in nephrology.

Limelight Bio is developing novel gene therapy technologies that greatly expand upon the set of disease that can be treated with clinically-validated AAV vectors, including genetic diseases caused by large genes that exceed the payload capacity of AAV or by autosomal dominant inheritance patterns that cannot be addressed using traditional gene replacement approaches. In addition to both AAV-mediated and non-viral gene delivery technologies that address these unmet needs, the company is developing a portfolio of conventional AAV-based gene replacement programs for prioritized genetic retinal dystrophies.

Marengo Therapeutics is pioneering first-in-class therapeutics that activate the right immune response to promote lifelong protection against cancer. Marengo’s proprietary Selective T Cell Activation Repertoire (STAR) platform leverages an extensive biological understanding of T cell function and receptor signaling to create a world in which everyone’s immune system can defeat cancer.

Co-led therapeutics team within Apple Tree Partners, a $1.5 billion venture capital fund dedicated to the life sciences.

Syntimmune developed novel antibody therapies for inflammatory diseases and severe toxicities. Syntimmune’s lead program, SYNT-001, specifically blocks FcRn-IgG interaction, resulting in the rapid clearance of pathogenic IgG important in a variety of antibody-mediated diseases. The company was acquired by Alexion in November 2018 for up to $1.2 billion.

Research focused on novel therapeutic strategies for autoimmune diseases, with a particular interest in immunomodulatory agents capable of fostering or restoring tolerance in the context of type 1 diabetes and related diseases.

Member of investment team responsible for managing $315 million private equity fund focused on structured investments in biopharmaceutical drug development. Significant responsibilities across all aspects of the investment process, including deal sourcing, diligence, negotiation, execution, management and exit.

Provided advice to leading healthcare companies on financings and strategic engagements, with a primary focus on the biotechnology and medical device industries. Advised on completed equity and debt financings totaling over $1.3 billion and on completed M&A transactions totaling over $500 million.